

Safe harbor statement

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words "believe," "expect," "anticipate," "intend," "estimate," "outlook," "will," "may," "continue," "should" and similar expressions identify forward-looking statements.

Forward-looking statements include statements regarding: objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company's markets; the impact of regulatory initiatives; and the strength of competitors. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in records and other data available from third parties.

Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and may be beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements.


The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation, and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations.

By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions.



Chr. Hansen is a microbial powerhouse

with leading market positions across different end-markets in food, health and agriculture





¹ Does not contribute to organic growth (50-50 JV with Lonza).

² Human Milk Oligosaccharides.


We address global challenges

with the Power of Good Bacteria™









FOOD CULTURES & ENZYMES



Our Good Bacteria can:





Extend shelf life of foods and protect



Create great healthy and



Support gut & immune health in



Potentially cure diseases as 'bugs



HEALTH & NUTRITION

Reduce use of production



Replace chemical pesticides in crop farming



We drive industry-leading profitable growth to grow a better world. Naturally.

Financial and non-financial ambitions until 2024/25



FINANCIALS Creating value for shareholders.

Industry-leading growth

• Mid-to high single-digit organic growth CAGR

Improving profitability

• Underlying expansion in EBIT margin b.s.i. before portfolio changes and FX

Strong cash flow generation

• Free cash flow b.a.s.i. to grow faster than absolute EBIT b.s.i.

PRODUCTS

More than 80% of revenue from sustainable products.

- 25m hectares covered with natural solutions
- 200m people consuming our probiotics
- 2m tons of yogurt waste reduced



PLANET

Limit global temperature rise to 1.5°C.

- 100% Renewable energy
- 100% Circular management of biowaste
- 100% Key packaging materials recyclable



PEOPLE

A diverse, engaged and safe workforce.

- 1:1 Female employees and women in management
- Top 25 Score in engagement matters survey
- < 1.5 Lost-Time Incident Frequency






We aim for more than 80% of our revenue to contribute directly to the United Nation's Global Goals


in % of gross revenue¹




FARMLAND TREATED WITH NATURAL SOLUTIONS² in m ha











¹ Continuing operations.

² Plant Health or silage inoculants.

³ New KPI, no previous data available. Excl. acquisitions.

Direct impact **Strong opportunity** Impact 17 PARTNERSHIPS FOR THE GOALS 8 DECENT WORK 8 13 CLIMATE ACTION 1 NO POVERTY ĬŧŧŧĪ Opportunity Indirect impact Limited opportunity

We focus on the three SDGs where we can make the strongest impact

✓		✓ ✓
✓		✓ ✓
✓		$\overline{\hspace{1cm}}$
		•
	✓	✓
	✓	✓
\checkmark		
	✓	
	✓	
✓		✓
	✓	✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓



Our 2025 Strategy embeds our commitment to sustainability across all pillars

Strategic ambition until 2024/25

Creating a
differentiated
bioscience company
with focus on
microbial and
fermentation
technology platforms

2020/21 - 2024/25 **2025 STRATEGY LEVERAGE** microbial platform to grow lighthouses and expand into new areas Divestment of Natural Colors completed EXTENO **EXTEND REINVEST** microbial platform in core platforms FC&E, through M&A and **Human and Animal Health** partnerships

2012/13 - 2018/19

NATURE'S NO. 1



We REINVEST in our core platforms

to defend and further strengthen our market positions in dairy and meat, Human and Animal Health



FOOD CULTURES & ENZYMES



Dairy and meat



Probiotics for fermented milk

HEALTH & NUTRITION



Human HealthDietary supplements
and infant formula



Animal Health
Cattle, swine
and poultry



We bring new innovations to dairy farmers

to help them produce more efficiently and sustainable





We have product solutions for both driving efficiencies and creating healthier, tasty, clean-label products.



CHY-MAX® SUPREME FOR HIGHER CHEESE YIELDS

Cost saving					
2,000 tons less milk ¹					
CO ₂ savings					
3,000 tons					



SWEETY® AND NOLA® FIT FOR LESS SUGAR

Cost saving						
~0.5% of cost of goods sold						
Health benefit						
Up to 20% reduction in added sugar						



FRESHQ® FOR LESS FOOD WASTE

Cost saving
5,000 tons saved milk ¹
CO ₂ savings
7,500 tons



¹ Illustrative example for average dairy producing 20,000 tons cheese and 100,000 tons yogurt and sourcing 300,000 tons of milk.

Antimicrobial resistance

is one of the top 10 treat to global health



EU to reduce the sale of antimicrobials for farmed animals and in aquaculture by 50% until 2030.

53% of antibiotics used by Chinese farmers were used as growth promoters in 2018.

Antimicrobial resistance is one of the top 10 treat to global health.

Global deaths linked to antibiotic resistant bacteria could rise from 700,000 today to 10 million by 2050.

75% of antibiotics used globally are given to animals raised for food.

Improving food & health

Consumers and regulators are calling for less antibiotic usage

in livestock productions – our Animal Health probiotics can be part of the solution







BOVAMINE®FOR DAIRY AND BEEF CATTLE

- Increase milk yield
- Reduction in pathogens
- Decrease in antibiotic drug cost



BIOPLUS® FOR SWINE

- Reduction in piglet mortality rate
- Decrease in feed used per kg weight gain
- Better defense against viral challenges



GALLIPRO® FOR POULTRY

- Feed cost savings
- Decrease in pathogens
- Same performance without AGPs



In Human Health we want to be the voice of science

and bring best-documented probiotics to supplements and food consumers






OUR STRAINS ARE THE BEST DOCUMENTED IN THE WORLD AND WE CONTINUE TO INVEST IN SCIENCE AND DOCUMENTATION

THE PROBIOTIC INSTITUTE² LAUNCHED TO EDUCATE HEALTH CARE PROFESSIONALS AND CONSUMERS ON THE BENEFITS OF PROBIOTICS

Number of hits by strain name¹







² Disclaimer: The Probiotic Institute is an online platform from Chr. Hansen's US subsidary Chr. Hansen Inc. And is is intended for U.S. audiences only.



We LEVERAGE our Microbial Platform to develop lighthouses

that bring microbial solutions to new applications in food, health, farming and pharma



FOOD CULTURES & ENZYMES



Bioprotection Reduce food spoilage

and increase food safety

Estimated addressable markets¹

EUR 200m	EUR 1b
2025	Long-ter

FUR 1bn rm EUR <100m

2025

Long-term

EUR >100m



Fermented Plant Bases

'Fermented milk' alternatives and fermented beverages





Plant Health

Microbial crop protection for more sustainable farming



Live Biotherapeutics

Contract manufacturing for live biotherapeutics (Lonza JV)



HMOs

Prebiotics for infant formula (Jennewein)

EUR 400m 2025

EUR >1bn Long-term EUR 150-200m

2025

EUR >1bn

Long-term

EUR >400m

2025

EUR >1bn

Long-term

LIGHTHOUSE: New business area of strategic importance with minimum revenue potential of EUR 100m per year and above Group growth rates.



¹ Management estimates.

We develop bioprotective cultures

that can extend shelf life and increase food safety across a number of applications





			• •				
APPLICATION		FERMENTED MILK	CHEESE	FERMENTED MEATS	OTHER MEATS & FISH	DAIRY & MEAT ALTERNATIVES	FRUITS & VEGETABLES
Value	Extend shelf life & reduce food waste	\checkmark	\checkmark	\checkmark		\checkmark	
proposition	Clean labelling & food safety		\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Carabilities	Product offering	•		•			
Capabilities	Commercial/ market access						
Opportunity	Penetration today	~10%	<5%	~10%		<1%	



Fermented Plant Bases: New emerging lighthouse

captures trend towards alternative protein sources and healthier beverages





GROWTH DRIVERS




Changing consumer preferences with focus on health and more sustainable consumption



Government and NGO support driven by global climate agenda and increasing protein demand



Improving product quality, availability and pricing





We use fermentation to transform proteins into great foods

- no matter which base



		NU		NAL VAL	.UE	ENVIRONMENTAL IMPACT Per 1kg					SOLUTIONS		
		Calories (kcal)	Protein (g)	Calcium (mg)	Vitamin B12 (μg)	Water footprint in l	Carbon footprint in kg CO ² eq.	Land use in m²	÷		indication areas	ductivity	
Cow's m	nilk	65.1	3.33	120	0.24	1,020	23-52	33-158	FERMENTATION ture, taste, less sugar/salt	BIOPROTECTION helf life extension, clean abelling, food safety	JITCS novel	ENZYMES Ictose reduction, productivity	
Nuts	Coconut milk	31	0.21	18	-	9,063	1.5	4.3	FERMENT for texture, taste,	s —	PROBIC for gut health, immunity,	10	
Cereals	Soy milk	37.1	3.31	12	-	1,6441	0.54	1.4	fort	for	ut healt	for coagulation,	
Cereais	Oat milk	42.6	<0.46	1	-	1,0441	0.54	1.4			forg	for c	



We have a strong product pipeline in Plant Health

to bring biological crop protection solutions to market





PRODUCT PIPELINE TARGET CROPS Drive penetration in sugarcane in Brazil and expand in LATAM **QUARTZO® ACCUDO®** Biostimulant launched in South Korea; awaiting EU registration (FY21) *In-furrow applications:* Sugarcane First biofungicide First biofungicide to be launched (FY21) Coffee Fruits & vegetables Further products in development and registration **PRESENCE®** Drive penetration in soy in Brazil and expand in LATAM Seed coating: **AVODIGEN®** Drive adoption in North America and register for other geographies Soy Corn Further products in Beans

development and

registration



50% reduction

in chemical pesticides targeted by EU until 2030¹

27

Chemicals may be banned in India which is the fifth largest market for crop protection²

Cotton

¹ See European Commission EU Green Deal, Farm to Fork strategy.


² Indian Government published draft proposal to ban 27 chemical pesticides that present 40% of total crop protection sales in May 2020.

Our joint venture Bacthera


is a crucial enabler for the emerging live biotherapeutics or 'bugs as drugs' industry



RAPIDLY EMERGING MARKET FOR LIVE BIOTHERAPEUTICS



FULL SUPPLY CHAIN OFFERING WITH TRULY DISTINT CAPABILITIES



- Organization established (+50 FTEs) and first customer contracts signed; strong pipeline
- Supply chain build-out progressing well with first phase of investments completed (EUR 90m in total FY20-22 split between CHR/Lonza)

EUR >1bn

long-term

market potential

EUR 150-200m


in 2025 (only

(clinical trial)

We EXTEND our Microbial Platform through M&A and partnerships

to further enhance our microbial and fermentation capabilities





COMPLEMENTED WITH BOLT-ON ACQUISITIONS

2015 **DIAL** 2016 **NPC**

(][)

2016 **LGG**



2018 **Hundsbichler**



2020

HSO

2020 UAS Labs



2020 Jennewein



STRONG NETWORK OF GLOBAL PARTNERS


















High growth in global HMO market

driven by consumer demand for 'close-to-nature' infant formula and increasing scientific evidence






HMOS ARE THE THIRD LARGEST COMPONENT IN HUMAN MILK Nutrient composition in human milk



Selected health benefits:

- Support neuronal & brain development of infants
- Reduce risk of NEC in pre-terms infants
- Improve digestive health & strengthen immune system
- Immunomodulatory effect
- Act against bacterial/viral pathogens and toxins

DEMAND FOR HMOS IS EXPECTED TO INCREASE MEANINGFULLYAddressable market in EUR¹



Growth drivers:

- Premiumization trend in infant formula to drive penetration
- Regulatory approval in NA, Europe and parts of LATAM and Asia; further countries to come
- Increasing scientific evidence around health benefits
- Combination products and new applications



¹ Management estimates.

We implement our 2025 Strategy across five dimensions

How to win

1	CUSTOMERS	Further expand customer base and global reach	and excel in customer centricity by expanding route-to-market, adding resources in application, sales and marketing and advancing our digital agenda.
2	INNOVATION	Accelerate new product development and commercialization	with dedicated project management and a new governance set-up, as well as through the expansion of R&D partner network and digitalization.
3	OPERATIONS	Realize scalability benefits and operational efficiencies	through future capacity expansions, process innovations, robotics and automation.
4	PEOPLE	Safeguard culture and invest in talent management	with a commitment to diversity, creating a safe workplace, driving a mindset of best and attracting millennials.
5	PURPOSE	Drive sustainability agenda to Grow a better world. Naturally.	and committing to limit global temperature rise to 1.5 degrees.



We aim to further expand our global presence

and strengthen our position in emerging markets





¹ New application center or further expansion/investments during strategy period.



We have a strong and well-balanced R&D pipeline

INNOVATION

across core businesses and lighthouses to drive growth during 2025 Strategy period and beyond

		Short-term		Mid- to long-term
	DAIRY & MEAT	Maintain lead in core rang	e e.g. next generation dairy enzymes,	sugar reduction
	PROBIOTICS		Probiotic solutions f	for new food applications (beyond traditional yogurt)
FOOD CULTURES & ENZYMES	BIOPROTECTION	Fermented plant bases	3 rd gen fermented milk	Cheese and non-fermented meat
	DI ANT DACEC	Yogurt alternatives	Non-alcoholic beer	Cheese and meat alternatives
HEALTH & NUTRITION	HUMAN HEALTH	New strains for infant and	dietary supplements	
	ANIMAL HEALTH	Pet health	Next generation probiotic strains for	or swine and cattle
	,	≙ New biostimulant/biofung	icide	Next generation bionematicides




We will expand our production capacity

while realizing optimization initiatives and synergies from UAS Labs integration



MOST OF OUR CAPEX PROJECTS ARE CENTERED AROUND BUILDING CAPACITY

Illustrative based on capex spend in the last 5 fiscal years



WE CONTINUE TO DRIVE OPERATIONAL EFFICIENCIES THROUGH AMBITIOUS EFFICIENCY PROGRAMS ACROSS LEAN, PROCESS INNOVATIONS & DIGITALIZATION







Fermentation yields

Increasing fermentation yield of Animal and Plant Health production strains via fed-batch process

Downstream optimization

Optimizing separation techniques to reduce energy consumption and increase yields

Robots and automation

Reduce repetitive workload and manning e.g. via intelligent internal transportation system



We commit to further reducing our environmental footprint

OPERATIONS




through targeted initiatives in the areas of renewables, circular management of waste and recycling





AMBITION FOR GLOBAL OPERATIONS UNTIL 2024/25 compared to 2018/19








SBT-INITIATIVE JOINED IN JULY 2020 COMMITTING TO LIMIT GLOBAL TEMPERATURE RISE TO 1.5 °C



ACTIVITIES TO BE INITIATED DURING 2021/2022 TO START REPORTING IN LINE WITH TCFD RECOMMENDATIONS





We safeguard our culture and invest

in talent management and diversity





SAFEGUARD CULTURE & SUCCESSFUL ONBOARDING OF NEW EMPLOYEES

- Top 25% score in employee engagement survey
- 100% of new employees introduced to culture model
- 2019/20 performance: 100 % introduced



COMMITMENT TO TALENT MANAGEMENT AND DIVERSITY

- 1:1 ratio between female employees and managers
- 2019/20 performance: 43:37 ratio between female employees and managers



SAFE PLACE TO WORK


- <1.5 lost-time incident frequency
- 2019/20 performance: LTIF: 1.3



ATTRACTIVE COMPENSATION FOR MANAGEMENT

- Performance metrics aligned with shareholder interests
- In line with industry benchmarks





Executive compensation linked to sustainability

and closely aligned with shareholder interests; strong incentive component

SHORT TERM: ANNUAL INCENTIVE PROGRAM FOR CEO AND CFO

- Based on group financial and non-financial targets
 - Non-financial KPIs related to customer service, quality, diversity, safety and environment
- Bonus is paid as a minimum 1/3 in Restricted Stock Units and 2/3 in cash; normally accounts for 25-30% of total remuneration package

Organic growth	EBIT	FCF	Non-financial
40%	30%	10%	20%

In % of fixed pay ¹	Target	Max
CEO	70%	100%
CFO/EVP	50%	70%

LONG TERM: PROGRESSIVE THREE-YEAR INCENTIVE PROGRAM

- Requires personal investment in Chr. Hansen shares to participate
- Grant value estimated (based on Black-Scholes) at 20-25% of the remuneration package
- · Vest in full after three years

Target matching shares per investment of one share


In % of fixed pay ¹	Target	Max
CEO	80%	120%
CFO/EVP	60%	90%




¹ Base plus pension.

Strong governance

with diverse competencies and dual management system








Sustainability Board

is responsible for ensuring ownership, involvement and commitment from the entire business in defining, prioritizing and executing Chr. Hansen's sustainability objectives and activities



CHR HANSEN

Improving food & health

Sustainability ratings & rankings


Chr. Hansen regularly submit information about our performance to customers and investors via global reporting platforms, such as MSCI, Oekom, Eco-Vadis, Sustainalytics, the Carbon Disclosure Project, FTSE4Good and Sedex.

RATING	RANK	DESCRIPTION
**CDP	В	Above sector average (D)
MSCI 🌐	AA	▶ Robust product safety strategy, strong governance structures
SUSTAINALYTICS	4th of 121	Ranked 4 th in subindustry, Specialty Chemicals
ecovadis	94 th percentile	Awarded silver rating
FTSE4Good	✓	Chr. Hansen listed as a constituent
Corporate anights The Magazine for Clean Capitalism	No. 24	Ranked the 24 th most Sustainable Company in the World




A Decade of Action: Climate commitment to Business Ambition for 1.5°C and the Science Based Targets initiative

ROADMAP FOR SCIENCE-BASED TARGETS




ACTIVITIES IN SCOPE FOR MAPPING CO₂e







We aim for industry-leading organic growth

across our two segments



CONTINUING OPERATIONS










We remain committed to driving gross margin expansion

while investing in sales & marketing and R&D to support future growth






ADMINISTRATIVE EXPENSES % of revenue



R&D EXPENSES INCL. CAPITALIZATIONS % of revenue






Growth in free cash flow to exceed growth in absolute EBIT

supported by reduced investment needs until 2024/25

CAPEX SPENDING FOR CONTINUING OPERATIONS in EUR million and % of revenue



UAS LABS ACQUISITION AND PRODUCTION OPTIMIZATION ALLOW FOR PHASING OF CAPEX PROJECTS TO BEYOND THE STRATEGY PERIOD

Selection of large capex projects	Expected completion
Capacity upgrade, Roskilde	2021/22
Freeze dried & powder packaging, Copenhagen	2022/23
Additional fermentation capacity upgrades, US	2022/23
NEW: HMO production, Kalundborg (phase I)	2022/23-23/24
Additional fermentation capacity upgrades, Germany	2024/25
Innovation campus incl. application center & new pilot plant, Denmark	2022/23
Next large-scale dairy expansion	After 2024/25

Postponements of capex due to UAS Labs acquisition:

Expansion of Human Health facility, Roskilde

Dairy alternatives production



Creating shareholder value

with very clear capital allocation priorities

CAPITAL ALLOCATION PRIORITIES

Organic growth Investments into capacity, innovation and people To strengthen technology platform **Bolt-on acquisitions** and/or expand market access Ordinary dividend¹ 40-60% of net income Distribution of excess cash Extraordinary dividend or share buy-back

WHAT WE WILL NOT DO

- Pursue acquisitions in unrelated areas
- Expand outside microbial and fermentation platform
- Expand enzyme business outside food enzymes
- Become an integrated solutions provider
- Become a full value-chain pharma company



¹ The dividend proposed will depend on the Board of Directors' assessment of factors such as business development, growth strategy, current leverage and financing needs, and there is no guarantee that an ordinary dividend will be proposed or declared in any given year.

Financial calendar Contacts Camilla Lercke July 8, 2021 **Anders Mohr** Head of Sustainability Interim Report Q3 2020/21 VP Group Strategy & Investor Relations DKCALE@chr-hansen.com DKAMC@chr-hansen.com October 14, 2021 **Louise Rosenmeier** Annual Report 2020/21 **Annika Stern** Sustainability Manager Senior Investor Relations Officer DKLORO@chr-hansen.com November 24, 2021 DKASTE@chr-hansen.com Annual General Meeting 2021

